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The recommendations reported below have been the matter of a consensus within the working group, 
they are based on the evidence available, on data from the literature and on the most recent results of 
epidemiologic investigations. Needless to say, they are likely to be affected by any change that may  
occur in the state of knowledge. 
 
The main goal of these recommendations is to arrive at a decrease in the incidence of early-onset group 
B streptococcal infections in neonates. 
The secondary objectives are to standardize the preventive strategies for the management of pregnant 
women, to optimize laboratory techniques for detecting GBS and to suggest an updated algorithm for the 




SYMBOLS AND ABBREVIATIONS   
 
CDC   Centers for Disease Control and Prevention, Atlanta, USA  
CNA   Colistin-Nalidixic acid  
CRP   C-reactive protein 
CSF   Cerebrospinal fluid  
EOD   Early-onset disease  
FBC   Full  blood cell count 
GBS   Group B streptococcus 
GBS EOD Group B streptococcal early-onset disease 
IAP   Intrapartum antimicrobial prophylaxis  
ISP   Institut Scientifique de la Santé Publique, Bruxelles, Belgique 
IV  Intra-venous 
LIM   LIM broth (Todd-Hewitt broth with CNA) 
LOD   Late-onset disease 
OIA   Optical Immuno Assay 
PPROM  Preterm (< 37 weeks gestation) premature (before the onset of labor) rupture of 
membranes 
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1. INTRODUCTION  
1.1. The issue of EARLY-ONSET GROUP B STREPTOCOCCAL DISEASE (GBS 
EOD) 
 
Since the seventies, the incidence of neonatal group B streptococcal sepsis and meningitis has 
increased dramatically in all industrialized countries. Today, GBS is identified as the leading cause of  
invasive bacterial infections in neonates. The reported attack rates for the early-onset disease (EOD) 
(birth to age 7 days) range from 0.5 to 4 cases per 1,000 live births. As regards the late-onset form 
(LOD), which affects infants aged > 1 week, the attack rate is close to 0.5 per 1,000 live births. 
The early-onset form of GBS disease typically occurs in the first 24 hours of life, with fulminant 
sepsis or pneumonia and less often with meningitis. Despite intensive supportive care, diagnostic and 
therapeutic progress, these infections have remained associated with high mortality (5 - 20 %) and 
morbidity; more than 30 % of infants recovering from meningitis present long term neurologic sequelae.  
In perinatal infections or EOD, GBS is transmitted vertically to the newborn from the vagina of a 
typically asymptomatic colonized woman during labor and delivery. In addition to colonization with GBS, 
other factors increase the risk for GBS EOD.  These include prematurity (gestation < 37 weeks), 
intrapartum fever (temperature >= 38°C), duration of amniotic membrane rupture >= 18 hours, previous 
delivery of an infant with invasive GBS disease and GBS bacteriuria during the current pregnancy.   
Furthermore, GBS also cause 15-25 % of the cases of postpartum febrile morbidity with or without 
bacteriemia and induce maternal complications and sterility  succeeding post-partum endometritis.  
Because of the continuing magnitude and severity of GBS disease, several preventive strategies have 
been evaluated. The reference recommendations were published by the CDC in 1996, and were 
reevaluated and updated in 2002. Maternal intrapartum antibioprophylaxis is currently considered to be 
the most effective strategy to decrease the incidence of EOD. However the cost of prenatal screening and 
antibioprophylaxis, as well as the selective pressure that antibiotics may have on the bacterial flora of 
mother and newborn still generate much controversy.  
In Belgium, as in many European countries, no national guidelines for the prevention of GBS EOD 
are currently available. Nevertheless some hospitals have implemented strategies to decrease perinatal 
GBS infections and obstetric programs already include a GBS prevention policy. 
 
1.2. Belgian background 
1.2.1.Epidemiology 
Belgium does not escape the endemic situation of GBS infections observed in most industrialized 
countries. 
The main characteristics of GBS epidemiology and neonatal infections reported in Belgium are 
presented in Table 1.  These data are based on different studies conducted by the Belgian reference 
laboratory for GBS  in collaboration with the section of epidemiology of the ISP-WIV. 
Table 1 :  Characteristics of GBS epidemiology and neonatal infections in Belgium (1995-2001)  
Early-onset disease 
 Attack rate in 1999 2 per 1,000 live births 
 Mortality > 14 % 
 Meningitis  10 % 
 Serotypes  III predominant (43 %), followed by II (20 %), Ia (16 %) and 
Ib (13 %) and V (9 %), very rare IV 
 Obstetrical risk factors presence in only 40 % of cases 
 
Late-onset disease 
 Occurrence about 1 case for 5 early-onset diseases 
 Serotypes III highly predominant (86 %) 
 
Pregnant women  
 Rectovaginal colonization 13-25 % 
 
Resistance to  
 Erythromycin 10-15 % 
 (Erythromycin crossed-resistance with clindamycin 80 %)   
 
Between 1991 and 2001, GBS caused 37.9 % of early-onset sepsis and meningitis and no 
significant trend was demonstrated.  The second most frequent cause of EOD was E.coli (11.4 %); a 
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decline in the rate of E.coli and other Gram negative bacilli infections has occurred. Listeria 
monocytogenes, another important neonatal pathogen, was identified in 3.9 % of EOD.  
The rates of recto-vaginal colonization among pregnant woman range locally from 13 to 25 %, or 
even 35 %.   
In 1999, the attack rate of GBS-EOD was 2‰ live births. Due to methods used for collecting these 
data, they are probably underestimated. Only 40 % of the cases were linked to at least one of the 5 
additional risk factors. 
 
1.2.2. Compliance to prevention policies 
 
In 1998, a survey was directed to all gynaecologists and hospital biologists from the French-
speaking Community. It showed that though 90,5 % of the departments of obstetrics complied to a 
prevention policy, only 66 % of them had a written protocol. Referring to the CDC guidelines, 30 % of the 
protocols in use recommended a preventive strategy of acceptable conformity. Individual practices of 
obstetricians were usually in agreement with the strategies suggested by hospitals. The best compliance 
to the CDC guidelines was reported among young obstetricians and in hospitals from the Brussels area.  
In 1999, a similar study was conducted in the Flemish Community. It revealed that the Flemish 
attitudes were different from those observed in the French-speaking Community in the sense that the 
Flemish turned out to be less keen to apply the strategies endorsed by the CDC. While 84 % of 
obstetricians from the French-speaking Community had chosen the prenatal screening-based approach, 
in the Flemish Community, 38 % of obstetricians opted for a risk-based option.  
As far as the antibioprophylaxis is concerned, both studies reported that the regimens 
recommended were often  inadequate and the choice of antibiotics sometimes inappropriate. 
 
1.2.3. Laboratory practice 
 
The 1998 survey also evaluated the microbiological procedures used for GBS screening. 
Comparing once again existing practices with the CDC guidelines, it turned out that only 2% of 
laboratories used adequate prenatal screening methods. It should be stressed that one culture medium 
that was specifically recommended was not marketed in Belgium at that time.  However, more than 60 % 
of the laboratories processed their specimens for GBS screening with acceptable culture and 
identification methods. The main problem with the culture methods was a lack of sensitivity to a prenatal 
screening. 
 
All these observations clearly highlighted the need for promoting updated, widely accepted 
guidelines to reduce the perinatal GBS burden. The first step was to reach a consensus and then 
to issue national recommendations  
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2. RECOMMENDATIONS 
2.1. PREVENTIVE STRATEGY 
 
Several approaches have been proposed, mainly chemoprophylaxis and immunoprophylaxis.  
 
Immunoprophylaxis is believed to be the most promising durable and cost-effective method for 
preventing EOD and LOD. However, this approach is not available yet, with different types of vaccines 
still being developed or tested on healthy subjects. 
 
In the late 1980’s clinical studies confirmed the fact that administering intrapartum penicillin G or 
ampicillin intravenously to GBS carriers led to a decrease in the transmission and incidence of the 
infection. This observation has led to a strategy with two options for the identification of mothers giving 
birth to a newborn at risk of developing GBS EOD. Intrapartum antibiotics could be recommended :  
• either for women with recognized risk factors (risk-based approach),  
• or for women with a positive prenatal screening for GBS vaginal colonization (culture- or 
screening-based approach). 
Both penicillin G and ampicillin have been recommended, although the former is preferred for its 
narrower spectrum (other antibiotics must be given in case of penicillin-allergy). 
 
A recent CDC-sponsored multistate study compared the two strategies and found that a screening-
based approach was > 50% more effective than the risk-based approach in  preventing perinatal GBS 
disease. The screening-based approach was more effective because it identifies women without 
additional maternal or intrapartum risk factors, and furthermore  women with GBS positive screening were 
usually more likely to receive their prophylaxis than women with >= 1 risk factor when this option was 
chosen. 
  
The implementation of these recommendations increases the use of antibiotics. Needless to say, 
the costs and risks they generate must be balanced against the benefits reaped. The main direct costs 
result from GBS prenatal screening cultures and antimicrobial prophylaxis.  Among the risks are potential 
adverse effects (mainly allergic reactions); other unintended consequences of an increased use of 
antibiotics  are the risk  of emergence of GBS strains resistant to standard therapies but also the risk of a 
shift to serious infections caused by other pathogens including more resistant bacteria 
(enterobacteriaceae, ampicillin-resistant coliforms,…). So far, such a trend has not been unequivocally 
observed, but this should be monitored with great vigilance.  
 
Recently intrapartum chlorhexidine vaginal flushing for all women admitted for delivery has been 
proposed under certain conditions. Preliminary results are encouraging but further studies are still 
needed. 
 
The following recommendations for the prevention of perinatal GBS disease are, with some 
amendments, very close to the revised recommendations issued by the CDC in August 2002. 
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2.1.1. Practical recommendations 
 
Obstetricians in conjunction with supporting laboratories and labor and delivery facilities should adopt the 
following strategy (Figure 1 or table 2). 


































Objective of screening to detect GBS  
• Screening to detect GBS colonization in each pregnancy will determine the need for intrapartum 
prophylaxis. At the time of labor or rupture of the membranes, intrapartum chemoprophylaxis 
should be given to all pregnant women identified as GBS carriers. 
 
Meaning of GBS bacteriuria during pregnancy 
• Women from whose urine GBS was isolated in any concentration during their current pregnancy 
should receive intrapartum chemoprophylaxis as they are usually heavily colonized with GBS and 
are at increased risk of delivering an infant with early-onset GBS disease.  
o Labels on urine specimens from prenatal patients should clearly state the patient's 
“pregnant” status to assist laboratory processing and reporting of results.  
o Prenatal culture-based screening at 35-37 weeks' gestation is not necessary for women 
with GBS bacteriuria.  
Recto-vaginal GBS screening culture at 35-37 weeks’ gestation  
 
for ALL pregnant women 
 
≥ 1 Risk factor: 
       - Intrapartum fever ≥ 38°C *** 
       - ROM  ≥ 18 h   
 










Intrapartum prophylaxis NOT indicated
if YES 
 NO 
* if the onset of labor or rupture of the amniotic membranes occurs before 37 weeks’ gestation and there is a
significant risk of preterm delivery (as assessed by the clinician), an  algorithm for the management of GBS
prophylaxis  is suggested below (fig 2). 
**  currently, only one test shows appropriate sensitivity and specificity: the Strep B OIA (BioStar) 
*** if amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against
GBS should replace the GBS prophylaxis. 




! Facultative ! : 
Intrapartum rapid GBS antigenic test**
Positive 
YES
Unless patient  had a previous infant with GBS invasive disease
or GBS bacteriuria during the current pregnancy
or delivery occurs < 37 weeks’ gestation*
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o Women with a symptomatic or asymptomatic GBS urinary tract infection detected during 
pregnancy should be treated according to current standards of care for urinary tract 
infection during pregnancy.  
 
Other indications for intrapartum prophylaxis 
• Women who have previously given birth to an infant with invasive GBS disease should receive 
intrapartum chemoprophylaxis; prenatal culture-based screening is not necessary for these 
women.  
• If the result of the GBS culture is not known at the onset of labor, intrapartum chemoprophylaxis 
should be administered to women with any of the following risk factors (as in risk- based 
preventive strategy): gestation <37 weeks, duration of membrane rupture >=18 hours, or a 
temperature of >=38.0ºC. Women with known negative results from vaginal and rectal GBS 
screening cultures within 5 weeks of delivery do not require prophylaxis to prevent GBS disease 
even if any of the intrapartum risk factors should develop.  
 
Table 2 : Summary of the strategy for prevention of perinatal GBS disease  
 
- Vaginal and rectal GBS screening cultures at 35-37 weeks’ gestation for ALL pregnant 
women (unless patient had GBS bacteriuria during the current pregnancy or a previous infant 
with invasive GBS disease). 
 
- Intrapartum prophylaxis IS INDICATED for women with: 
o Previous infant with invasive GBS disease 
o GBS bacteriuria during the current pregnancy 
o Positive GBS screening culture during the current pregnancy (unless a planned cesarean 
delivery is performed in the absence of labor or amniotic membrane rupture) 
o Positive GBS rapid screening antigenic test* – if performed – at the time of labor (unless 
a planned cesarean delivery is performed in the absence of labor or amniotic membrane 
rupture) 
o Unknown GBS status (culture not done, incomplete, results unknown or negative GBS 
rapid screening antigenic test performed at the time of labor) AND any of the following: 
 Delivery at < 37 weeks’ gestation** 
 Amniotic membrane rupture >= 18 hours 
 Intrapartum temperature >= 38°C***. 
 
- Intrapartum prophylaxis IS NOT INDICATED for women with: 
o Previous pregnancy with a positive GBS screening culture (unless a culture was also 
positive during the current pregnancy) 
o Planned cesarean delivery performed in the absence of labor or amniotic membrane 
rupture (regardless of maternal GBS culture status) 
o Negative vaginal and rectal GBS screening culture in late gestation during the current 
pregnancy, regardless of intrapartum risk factors.  
 
*  currently, only one test has appropriate sensitivity and specificity: the Strep B OIA (BioStar) 
**if the onset of labor or rupture of amniotic membranes occurs at <37 weeks’ gestation and there is a significant 
risk for preterm delivery (as assessed by the clinician), an algorithm for the management of GBS prophylaxis is 
provided suggested  below (fig. 2). 
*** if amnionitis is suspected, a broad-spectrum antibiotic therapy that includes an agent known to be active 
against GBS should replace the GBS prophylaxis. 
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Threatened preterm delivery 
• Women with threatened preterm (<37 weeks' gestation) delivery should be assessed for the need 
for intrapartum prophylaxis to prevent perinatal GBS disease. An algorithm for the management 
of women with threatened preterm delivery is provided (Figure 2). Other management 
approaches developed by individual physicians or institutions may be appropriate.  
Use of antimicrobial agents for GBS not recommended before labor and delivery 
• In the absence of a GBS urinary tract infection, antimicrobial agents should not be used before 
the intrapartum period to treat GBS colonization. Such treatment is not effective in eliminating 
carriage or preventing neonatal disease and may cause adverse consequences.  
GBS and planned cesarean delivery 
• GBS colonized women who have a planned cesarean delivery performed before the rupture of 
the membranes and the onset of labor are at low risk for having an infant with early-onset GBS 
disease. These women should not routinely receive intrapartum chemoprophylaxis for perinatal 
GBS disease prevention, but should receive, if indicated, their regular cesarian-prophylaxis after 
clamping the umbilical cord.  
Rapid screening for GBS at time of labor and delivery 
• For women with prenatal negative cultures for GBS, or of unknown status, a rapid screening test 
could be carried out with the Strep B OIA test; a positive result should be considered as a positive 
screening, whereas a “negative result” should be considered as  “unknown result for GBS status”.    
Newborns: routine use of an antimicrobial prophylaxis for GBS not recommended 
• Routine use of an antimicrobial prophylaxis for newborns whose mothers received an intrapartum 
chemoprophylaxis for GBS infection is not recommended. However, therapeutic use of these 
agents is appropriate for infants with clinically suspected sepsis and for newborns at very high 
risk of developing an early-onset disease. An updated algorithm for the management of infants 
born to mothers who did or did not receive an intrapartum chemoprophylaxis for GBS infection is 
provided in figure 4. These algorithms are not exclusive approaches to the management of 
infants; variations that takes into account individual circumstances or institutional preferences 
may be appropriate. 
 
Figure 2 : Sample algorithm for GBS prophylaxis for women with threatened preterm delivery.  The algorithm 
is not an exclusive course of management.  Variations that incorporate individual circumstances or 
institutional preferences may be appropriate (CDC, 2002). 
 
Onset of labor or ruptures of membranes at <37 weeks’ gestation with 
significant risk for imminent preterm delivery 
No GBS culture
Obtain vaginal and 
rectal GBS culture 
and initiate IV 
penicillin 
Penicillin IV  








*   Penicillin should be continued for a total of at least 48 hours, unless delivery occurs sooner.  At the
physician’s discretion, an antibiotic prophylaxis may be continued beyond 48 hours when treating a
woman with a positive GBS culture if delivery has not yet occurred.  For women who are GBS
positive, antibiotic prophylaxis should be reinitiated when labor likely to proceed to delivery occurs
or recurs. 
** If delivery has not occurred within 4 weeks, a vaginal and rectal GBS screening culture should be
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2.1.2. Screening methods 
 
2.1.2.1. Specimen collection and transport (table 3)   
• Collection of specimens for culture may be conducted in the outpatient clinic setting by a health-care 
provider (or by the patient, with appropriate instruction).  This involves swabbing the lower vagina and 
rectum (i.e., through the anal sphincter). Because lower vaginal as opposed to cervical cultures are 
recommended, cultures should not be collected by speculum examination.  
• Specimens should be placed in a non-nutritive transport medium (e.g., Amies or Stuart's without 
charcoal). In these conditions, viability of GBS is guaranteed for at least 48 hours at room 
temperature or in a fridge (2 - 8°C).   
• Specimen labels should clearly identify that the specimens are intended for group B streptococcal 
culture.  Swabs should reach the lab within 48 hours of collection. 
 
Table 3  Obstetrician’s procedure for collecting clinical specimens for  prenatal GBS screening cultures  
 PRENATAL GBS SCREENING 
WHEN    
Collect specimen at 35-37 weeks of gestation. 
WHO   
ALL pregnant women at that time of pregnancy. 
 
WHICH SPECIMEN    
Vaginal swab : lower vagina 
+ rectal swab : through the anal sphincter  
MATERIAL   
One (or two) swab(s) for both collection sites 
placed in non-nutritive transport medium (e.g. Amies or 
Stuart’s without charcoal) 
STORAGE & TRANSPORT   
Transfer specimens to the laboratory within the day.   
If any delay, refrigerate specimens (2 to 8°C), maximum 48 
hours 
REQUESTING FORM     
Clearly request culture for “GBS Screening” 
Communicate the address of expected delivery facility  
 
2.1.2.2 Laboratory procedures 
Culture procedures that maximize the likelihood of GBS recovery are required for prenatal 
screening (figure 3). They must therefore have the highest possible sensitivity. 
 
• Upon reception, swabs for GBS prenatal screening cultures should be inoculated into a selective 
broth medium (Todd-Hewitt broth with colistin, 10mg/L and nalidixic acid, 15 mg/L = LIM broth), 
incubated overnight at 35-37°C, and subcultured onto Granada medium, or, should it be 
unavailable, on sheep blood agar. For Granada medium, a maximum of 4 specimens can be 
subcultured on the same plate, but a plate cannot be  reused another day. Plates of Granada 
medium should be incubated anaerobically at 35-37°C, 18-24 hours; aerobic incubation is 
possible if a glass coverslip is placed over the inoculated surface (coverslips do not need to be 
sterile).  Inspect and identify organisms suggestive of GBS. The development of orange or red 
colonies on Granada after 18-24 hours of incubation is specific (100%) to GBS.  (On sheep 
blood, colonies suggestive of GBS should be specifically identified with a grouping latex 
agglutination test or other tests for GBS antigen detection). 
• Laboratories should report a qualitative culture result for the recto-vaginal screening as “GBS 
Prenatal screening POSITIVE, or negative” at least to the anticipated site of delivery (when 
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known) and to the health-care provider who ordered the test (Important: the laboratory should not 
give a quantitative result).   
• Before inoculation in the selective enrichment broth, some laboratories may inoculate the swab 
onto CNA sheep blood agar or Granada medium plate.  This should be done only in addition to 
(and not instead of) inoculation in selective broth.  If this primary culture is positive for GBS, the 
broth can be discarded, thus shortening the delay before which the culture results are available. 
• Health-care providers should inform women of their GBS screening test result and the 
recommended interventions. 
 














































Overnight   at 35-37 °C 
18-24 hours  at 35-37°C  anaerobic  
(or aerobic +  glass coverslip ) 
… . ....         
    
Vaginal & rectal swab  
(or vaginal swab, less effective) 
   Orange colonies      No orange colonies
     GBS Screening      GBS Screening
        POSITIVE                 Negative 
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2.1.3. Regimens for antimicrobial prophylaxis 
 
To date, all human isolates of GBS have remained uniformly susceptible to penicillin G.  They are 
also susceptible to other β-lactams, cephalosporins, carbapenems and vancomycin.  
Acquired resistance is observed for several antimicrobial agents : resistance rate to tetracyclines 
has reached nearly 90 %  and more recently resistance to erythromycin and clindamycin is emerging. In 
Belgium, resistance to erythromycin and clindamycin currently occurs in about 15 % of isolates ; in some 
areas in North America this resistance can reach up to 30 %.   
GBS are naturally resistant to bacitracin, nalidixic acid, trimethoprim-sulfamethoxazole, 
metronidazole and aminoglycosides.  Nevertherless, when gentamicin is combined with either penicillin G 
or ampicillin, there is a synergistic killing. 
 
Penicillin G is presented as the 1st choice, as a result of its narrower spectrum.  Penicillin allergy is 
reported by 12 % of all pregnant women. However, skin tests show that only 10 – 20 % of those cases 
have a proven penicillin allergy. 
In case of confirmed penicillin allergy, clindamycin is used, though its efficacy in reducing early-
onset septicemia has not yet been investigated.   
The different recommended options for intrapartum antimicrobial prophylaxis are summed up in 
table 4. 
 





Penicillin G, 5 million units IV initial dose; then 2.5 million 
units IV every 4 hours until delivery * 
 
In case of penicillin allergy :  
• at low risk for anaphylaxis 
 
_____________________________ 
•  at high risk  for  anaphylaxis 
  
• Cefazolin, 2 g IV initial dose, followed by 1 g IV every 
8 hours until delivery  
______________________________________________ 
• Clindamycin, 900 mg IV every 8 hours until delivery  
If GBS strain resistant to clindamycin : seek the 
advice of an  infectiologist.  
 
• During prenatal care, the patient’s history of penicillin allergy should be assessed to determine 
whether she is at high risk for anaphylaxis, i.e., has a history of immediate hyper-sensitivity 
reactions to penicillin (e.g., anaphylaxis, angioedema, or urticaria) or a history of asthma or other 
conditions that would increase the danger of anaphylaxis.  
• Women who are not at high risk for anaphylaxis should be given cefazolin.  
• For women at high risk for anaphylaxis, clindamycin and erythromycin susceptibility testing 
should be performed on isolates obtained during GBS prenatal carriage screening. Women with 
clindamycin-susceptible isolates should be given clindamycin, 900 mg intravenously every 8 
hours until delivery.  
• If the strain is resistant to clindamycin, an infectiologist’s advice should be requested as soon as 
this information becomes available. 
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2.2. Management of the neonate at risk for early-onset Group B streptococcal 
disease (GBS EOD) 
 
The majority  (95%) of children with GBS EOD will become symptomatic within the first 24 hours 
after birth. 
Though the management of symptomatic neonates and/or neonates at high risk of infection is well 
defined, the management of asymptomatic neonates is more problematic.  
An approach for the empirical management of infants born to women who received or should have 
received IAP to prevent GBS EOD or to treat suspected chorioamnionitis, is provided (figure 4).  One 
objective of developing an algorithm for the management of newborns was to minimize unnecessary 




A full diagnostic evaluation should be carried out for any infant with clinical signs of sepsis and 
empirical antibiotic therapy (ampicillin + aminoglycoside) should be started regardless of IAP, other 
obstetrical risk factors or maternal GBS status.  
Because of sub-optimal sensitivity and specificity, and of poor predictive value for infection, routine 
use of urine antigen and cultures of mucous membranes or body surfaces cannot be recommended.  
 
-Clinical signs of sepsis: infant with a combination of signs such as respiratory disturbance 
(apnea, grunting, tachypnea, cyanosis), cardiovascular (reduced capillary refill, hypotension, 
shock), central nervous system (lethargy, hypothermia, fever, seizures, apnoeic spells, irritability, 
bulging fontanel) or gastrointestinal  (poor feeding, abdominal distension).  
 
-Full diagnostic evaluation: full blood cell count (FBC) and differential, CRP level, blood culture, 
lumbar puncture if indicated and feasable (CSF analysis and culture), chest X ray , endotracheal 
culture (in intubated infants or if respiratory distress or RX infiltrate).  
A lumbar puncture is indicated only in neonates with clinical signs of meningeal inflammation 
(seizures, apnoeic spells, irritability, bulging fontanel). In cases of clinical instability, antibiotic 
therapy should be administered and LP should be deferred and performed later for cell count, 
chemistry and culture. 
 
2.2.2. Asymptomatic newborn 
 
2.2.2.1. Neonates at high risk 
 
Chorioamnionitis and PPROM (see 3.3.2) predispose to infection with Gram negative organisms 
and increase the risk of GBS infection in GBS colonized women. If a mother received intrapartum 
antibiotics for the treatment of suspected chorioamnionitis or in cases of PPROM, a full diagnostic 
evaluation should be carried out (see 2.2.1) and empiric antibiotic therapy (ampicillin + aminoglycoside) 
should be started in newborns regardless of the clinical condition at birth or other conditions.  
 
2.2.2.2. Neonates at low risk 
 
Routine use of antimicrobial prophylaxis for asymptomatic newborns whose mother received IAP is 
not recommended. An algorithm for the management of these newborns is suggested in figure 4.  
If no maternal IAP for GBS is administered despite indication being present (see table 2), data are 
insufficient on which to recommend a single management strategy. In that case or if IAP is administered 
but its duration is < 4 hours or if gestational age is < 35 weeks, limited evaluation and observation should 
be undertaken. 
  
• Limited evaluation: serial measurements of CRP and full blood cell count repeated at least 
at 12 and 24 hours of life.  
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Sepsis should be suspected based on repeated clinical and laboratory evaluations and if 
sepsis is suspected, a full diagnostic evaluation should be carried out (see 2.2.1.) and empiric antibiotic 
therapy should be started.  
   
• Lower and upper limits of neutrophils count vary with postnatal age. Sepsis should be 
suspected if leucopenia < 5000/mm3 or if neutrophilia is out of range of Manroe criteria (table 
5). 
Table 5. Manroe’s criteria for lower and upper limits of neutrophils 
Limits 0H 6H 12H 18H 24H 
Low 1800 5400 8000 8000 7200 
High 7000 13000 14400 13000 12500 
 
• CRP: the sensitivity of the test to predict a bacterial infection increases rapidly after birth but 
at least 6 to 12 hours after the onset of infection are necessary to reach an abnormal level. A 
significant increase between 2 serial dosages on samples taken over the first 8-48 hours of 
life has a sensitivity of almost 100% for an infectious status and normal levels for the 2 
dosages have a negative predictive value of 90 to 100% for an infectious status. The normal 
upper level of CRP depends on the laboratory. 
 
Empiric antibiotic therapy should include antimicrobial agents active against GBS as well as 
other organisms that might cause neonatal sepsis (e.g. ampicillin + aminoglycoside). Dosage and 
regimen of antimicrobiaI agents depend on diagnosis, post-natal age and birth weight (see Sanford 
guide).  IV immunoglobulins could be beneficial. 
 
Duration of antibiotic therapy varies depending on the results of the cultures and on the clinical 
course of the infant (table 6): about 48 hours for suspected sepsis but without clinical, biological or 
bacteriological confirmation; 10 days for proven sepsis; 14 days minimum for meningitis; 28 days for 
ventriculitis or osteomyelitis. If GBS infection is confirmed by culture, ampicillin should be replaced by the 
narrower spectrum penicillin and aminoglycoside should be administered during 3 to 5 days.  
 
Table 6 : Duration of antibiotic therapy 
Focus of infection Duration of therapy 
Suspected sepsis not confirmed by clinical, 
biological or bacteriological results 
 
48 hours 
Proven sepsis 10 days 
Meningitis 14 days minimum 
Ventriculitis or osteomyelitis 28 days 
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Figure 4:  Sample approach for the management of an asymptomatic newborn whose mother received 







   
If maternal IAP to prevent GBS EOD (see fig. 1 & 2) 
1- ASYMPTOMATIC NEWBORN “AT LOW RISK”  
If maternal antibiotics for suspected chorioamnionitis or PPROM :  
Full evaluation (c) & Empiric therapy (d)  
Gestational age 
>= 35 wks < 35 wks 
Duration of IAP(e) 
>= 4 hrs 
No evaluation 
< 4 hrs • Limited evaluation(a) 
• Observation 





(a) Includes serial full blood cell count and differential and CRP level 
(b) sepsis should be suspected on repeated clinical and laboratory investigation. Abnormal laboratory  
values: leucopenia < 5000/mm3, neutropenia or neutrophilia (see Manroe’s criteria, table 5), increase  
CRP level on two separate samplings. 
(c)  Includes full blood cell count and differential, CRP level, blood culture, lumbar puncture if indicated 
 (clinical signs of meningeal inflammation: seizures, apnoeic spells, irritability, bulging fontanel), chest  
Xray, endotracheal culture if intubated, respiratory distress or RX infiltrates 
(d) ampicillin + aminoglycoside: duration varies depending on the culture results and on the clinical  
course of the infant (see table 6). If GBS infection is confirmed by cultures, ampicillin should be  
switched to a narrower spectrum penicillin.  IV immunoglobulins could be beneficial. 
(e) Applies only to penicillin, ampicillin or cefazolin and assumes recommended dosing regimens  
(table 4).  For other agents used in penicillin-allergic patients, no data are available to suggest adequate 
durations for these regimens before delivery. 
 
2- ASYMPTOMATIC NEWBORN “AT HIGH RISK”  
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3. STATE OF THE ART 
3.1. Streptococcus agalactiae : the bacteria 
Streptococcus agalactiae, or Lancefield group B streptococci are Gram positive cocci, facultative 
aerobe, grown easily on a variety of bacteriological media. GBS may be further subdivided into serotypes 
based on type-specific capsular polysaccharide antigens. Currently nine serotypes are characterized : Ia, 
Ib, and II - VIII. A further classification is based on the presence of surface protein antigens c, R and X.  
Antibodies against type-specific polysaccharide antigens provide a good homologous passive protection.  
3.2. Epidemiology and  transmission  
3.2.1. Asymptomatic colonization 
The gastrointestinal tract is a natural reservoir for GBS and is the likely source of vaginal 
colonization. Vaginal colonization is unusual in childhood but becomes more common in late 
adolescence.  Currently, the prevalence of recto-vaginal colonization among pregnant women ranges 
from 10 to 20 % in North Europe, 20 % in Belgium and from 20 to 30 % in North America. GBS 
colonization is dynamic, it can be continuous, transient or intermittent.  The density of colonization also 
changes over time. Colonization is usually asymptomatic and carriers can only be identified by 
bacteriological testings. 
3.2.2. Transmission to neonates 
The rate of vertical transmission in neonates born to women colonized with GBS at the time of 
delivery ranges from 30 to 70 % (the mean being 50 %). Colonization of newborns results from vertical 
transmission of the organism from the mother, either in utero by ascending spread from the vagina or 
during passage through the birth canal. Transmission usually occurs after rupture of the membranes but 
can also occur through intact membranes. The likelihood of transmission is significantly influenced by the 
presence of a high genital inoculum at delivery.  Maternal intrapartum GBS colonization is a major risk 
factor for early-onset disease in infants.  However, colonization at an early stage of the pregnancy is not 
predictive of neonatal sepsis. Most newborns become colonized on the skin or mucous membranes but 
remain asymptomatic; among them, 1 to 4 % rapidly develop a clinical infection. Aspiration of infected 
amniotic fluid by the foetus can lead to stillbirth, neonatal pneumonia, or sepsis. 
In addition to exposure at birth, horizontally acquired (nosocomial) colonization of the neonate is 
related to poor hygiene and poor handwashing.  
3.3. Clinical manifestations 
3.3.1. Neonatal infections  
GBS invasive disease in neonates presents a bimodal distribution depending on their age at the 
onset of the infection. The syndromes of early- and late-onset disease (EOD and LOD) differ in clinical 
presentation, prognosis, epidemiological characteristics, and pathogenesis. (table 7)  
EOD occurs during the first week of life, but nearly 90 % of patients have signs of systemic infection 
at birth or develop these within 12 hours.  EOD accounts for approximately 80 % of GBS cases.  The 
source is typically the presence of GBS in the mother’s vaginal microflora. Most of the infants affected are 
full-term infants even if the attack rate is higher in premature and low weight neonates. Mortality rate is 
around 5-10 % in full-term neonates but can reach 40 %  in premature neonates.  
 LOD infection can affect infants between 8 to 90 days of age, with a median onset of about 36 
days, but LOD can occur up to 6 – 9 months of age. The acquisition of the GBS by the infants is more 
diverse and results more often from horizontal transmission.  The attack rate ranges from 0.5 to 1. 5 per 
1,000 live births. 
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Table 7 : Characteristics of Group B streptococcal Disease in infants 
Feature Early-onset Late-onset Late, late-onset 
Age at onset (median) <= 7 days (10 hours) 8 –90 days (36 days) > 90 days 
Infants affected 














Fever, non specific 
signs 
Site of infection 
Bacteriemia (40-55 %) 
Pneumonia (30-45 %) 
Meningitis (6-15 %) 
Bacteriemia without 
focus (55 %); meningitis 
(35 %) 
Bacteriemia without 
focus; osteoarthritis (5 
%); cellulitis/adenitis 
(2%) 
Serotypes  All Type III predominates Type III predominates 
Mortality 4 % - 15% 0 – 6 % < 5 % 
 
3.3.2. Additional risk factors for perinatal GBS disease 
Vertical transmission is a pre-requisite for the development of invasive GBS EOD. Consequently,  
the major determinant of risk is of course the presence of GBS in the birth canal at time of delivery 
but other important factors are also the absence of antibodies homologous to the type of the colonizing 
strain and the presence of other maternal risk factors (Table 8) 
Table 8 :  Maternal risk factors for GBS EOD 
- Chorioamnionitis or intrapartum fever (>= 38.0°C) 
- Labor prior to 37 weeks’ of gestation 
- Prolonged rupture of membranes (>= 18 hours) before delivery 
- GBS bacteriuria during current pregnancy  
- Previous infant with invasive GBS infection 
 
Intrapartum fever and Chorioamnionitis Infants born to women who have fever during labor (>= 
38.0°C) are at increased risk of developing an invasive infection.  In addition, clinical chorioamnionitis, 
evidenced by intrapartum fever accompanied by at least two additional clinical findings (foetal 
tachycardia, uterine tenderness, foul-smelling vaginal discharge, or maternal leukocytosis) is a marker of 
extremely high risk for the foetus, for sepsis in general as well as GBS EOD in particular. 
Prematurity and low birth weight  Smaller, less mature babies are at substantially higher risk 
than full-term infants, and the risk increases with decreasing gestational age and birth weight. 
Prolonged or premature rupture of membranes  Prolonged rupture of membranes for >= 18 
hours before delivery (PROM) is associated with an increased risk of GBS EOD.  Some have advocated 
considering PROM from 12 hours onwards.  Preterm (< 37 weeks’ gestation) premature (before the onset 
of labor) rupture of membranes (PPROM) in GBS colonized women is associated with an attack rate of 
EOD of 33-50 %. 
Maternal GBS bacteriuria  Some studies suggest that GBS bacteriuria during pregnancy may be 
associated with a higher neonatal GBS sepsis attack rate.  It is a sign of maternal GBS colonization, 
perhaps with a more virulent strain or with a higher inoculum, but it is not an indicator of extreme risk.   
Previous delivery of an infant with invasive GBS disease increases the risk of EOD in 
subsequent deliveries. 
 
However, it is important to realize that more than half of the GBS EOD cases occur after a delivery 
without any of these risk factors (in Belgium: 60 % of the cases).  
 
3.3.3. Pregnancy-related infections 
GBS disease is also common in pregnant women. Clinical manifestations include urinary tract 
infection (usually asymptomatic bacteriuria), pyelonephritis, intra-amniotic infection (chorioamnionitis), 
wound infections associated with cesarean delivery or episiotomy, endometritis (often with bacteremia), 
puerperal sepsis and occasionally meningitis, septic thrombophlebitis, or other serious complications. In 
some instances, GBS cause stillbirth and the evidence increasingly points to a causative role for these 
organisms in amnionitis and preterm delivery. 
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3.4.Laboratory methods for detection of GBS 
3.4.1. GBS culture-based screening methods 
Using classical cultures, detection of GBS at the onset of labor is too slow; therefore GBS must be 
detected before the delivery. The earlier this detection is performed during the pregnancy, the lower  the 
positive and negative predictive values for the presence/absence of GBS at time of delivery; the later this 
detection is performed, the higher the risk that results will not be available at the time of labor. As 
documented by numerous studies, the accuracy of prenatal screening cultures in identifying intrapartum 
colonization status can be enhanced by careful attention to the timing of the cultures, the anatomical sites 
swabbed and the precise microbiological methods used for the culture and detection of organisms. The 
most acceptable results are obtained by performing a culture between 35-37 weeks’ gestation, by 
combining a vaginal and a rectal sampling, and by using a culture technique that can detect low numbers 
of organisms (enrichment in selective broth, or use of media that allow easy recognition of GBS based on 
the production of a carotenoid pigment (e.g. Granada medium). 
3.4.2. Rapid testing methods to determine the GBS colonization status  
Rapid tests detecting GBS colonization at the onset of labor or rupture of the amniotic membranes 
might obviate the need for prenatal culture-based screening if their sensitivity and specificity were 
comparable to culture in selective broth media and if they yielded results rapidly enough to allow the 
administration of adequate intrapartum antibiotic prophylaxis to women identified as carriers. An adequate 
rapid intrapartum test must be as sensitive as culture (minimally 85% compared with culture of vaginal 
and rectal swabs inoculated into selective broth media), rapid so that results are available to clinicians in 
time for an appropriate IAP before delivery, and convenient for integration into routine laboratory use. 
Even a highly sensitive rapid detection test would not be adequate if the results were not available to 
clinicians 24 hours a day, 7 days a week. A rapid intrapartum test possessing the attributes described 
above offers the advantage of ascertaining the GBS colonization status before delivery among women 
who have had no pre-natal care. 
Currently, available rapid tests detect GBS antigen from swab specimens and are insufficiently 
sensitive to detect light colonization. As a result, they do not constitute an adequate replacement of 
culture-based prenatal screening.  If they are used when culture results are unknown at the time of labor, 
a positive result should be considered as a positive carrier status for the pregnant woman but a negative 
result has no  meaning.  
In 2002, a highly sensitive real-time PCR test has become available in North America and is very 
promising for a rapid appropriate detection of GBS on vaginal swabs. 
 
3.5.Preventive strategies 
In the 1990s, perinatal GBS disease prevention made much progress. In 1996, the CDC, in 
collaboration with other agencies, published guidelines for the prevention of perinatal GBS disease.  Two 
approaches were proposed: the risk-based and the screening-based approaches.  In 2002, the CDC 
published new revised guidelines following the reevaluation of the prevention strategies based upon data 
collected after the publication of the 1996 guidelines and based on available evidence and expert opinion. 
Amongst the changes made, the key modification is the recommendation of a single approach: the 
screening-based approach.  
3.5.1. Risk-based approach  
A number of obstetrical factors have been associated with an increased likelihood of early-onset 
GBS disease in the newborn. These include premature deliveries, prolonged ruptures of the membranes, 
intrapartum fever. The incidence of GBS disease is also higher in mothers < 20 years of age. Also more 
likely to be infected are neonates born to mothers with a history of birth of an infant with GBS disease, 
heavy colonization such as seen in GBS bacteriuria and low levels of GBS antibody.  
Based on these risk factors, the following risk-based preventive approach has been worked out 
(Figure 5): intrapartum antibiotic prophylaxis should be given to women with preterm labor (less than 37 
weeks), preterm premature ruptures of the membranes, rupture of membranes > 18 hours, previous 
sibling with GBS disease, or women with intrapartum fever (≥ 38°C). Prior identification of GBS 
bacteriuria is also considered as an indication for IAP. Using a number of assumptions, a strategy based 
solely on intrapartum risk factors could result in intrapartum treatment of about 18 % of women and 
prevent up to 68 % of neonatal GBS EOD.  
3.5.2. Prenatal screening-based approach 
On this approach, maternal rectovaginal cultures should be performed at 35 to 37 weeks’ gestation 
for all mothers without maternal risk factors (previous history of early-onset GBS disease in a sibling or 
maternal urinary tract infection with GBS). Culture techniques must be optimized to recover very small 
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numbers of GBS (subculture on sheep blood agar or Granada medium after a culture in a selective 
enrichment broth for instance). If the mother is GBS positive, she should be offered intrapartum 
antibioprophylaxis. This also holds if her GBS status is unknown,  but she shows intrapartum risk factors.  
If none of these conditions are present, no prophylaxis is necessary.  
       Figure 5. Risk-based preventive strategy for early-onset group B streptococcal disease, CDC 1996 
 
One or more of the following risk factors:     
  Previous infant with invasive GBS disease    
Give intra- 
 GBS bacteriuria this pregnancy → Yes → Partum 
 Delivery < 37 weeks of gestation?    Penicillin 
 Duration of ruptured membranes >18 hours     
 Temperature >38 °C     
 ↓     
  No  
      ↓  




3.6. Impact and implementation of guidelines 
 
Countries that have adopted perinatal GBS disease prevention guidelines similar to the United 
States have seen a decline in the incidence of early-onset disease of up to 70 %.  
Furthermore, the incidence of invasive GBS infections among pregnant women in the United States 
declined by 21% from 0.29 per 1,000 live births in 1993 to 0.23 in 1998, suggesting that increased use of 
intrapartum antibiotics also prevented some cases of maternal GBS amnionitis and endometritis. In 
contrast, the rate of late-onset disease remained fairly constant throughout the 1990s, suggesting that 
this intervention, as expected, is not effective against late-onset disease. 
 
With antimicrobial prophylaxis, potential adverse effects are expected :   
- The first expected consequence is the risk of antibiotic allergies including anaphylaxis. Even though  
penicillin allergy and risk of anaphylaxis exist, very few allergic events have been reported since the 
release of the 1996 CDC guidelines. 
- The second matter of concern is the potential rise of resistance in GBS. Among GBS isolates, no 
confirmed resistance to β-lactams has been observed to date and penicillin remains the agent of choice 
for IAP.  Ampicillin is an acceptable alternative, but Pen should be preferred for its narrower spectrum and 
because it may be less likely to select for resistant organisms. Acquired resistance has been observed 
and is increasing  for erythromycin and clindamycin. Currently, resistance to erythromycin and 
clindamycin occurs in about 15 % of isolates in Belgium; in some areas in North America this resistance 
can reach up to 30 %.  In light of these increasing resistances, IAP regimens for penicillin allergic patients 
have been modified according to the level of risk for anaphylaxis and according to susceptibility results if 
available.  
-The third potential unintended consequence of IAP is the increased incidence or resistance in non-GBS 
pathogens.  A few studies reported an increase in non-GBS pathogens in perinatal infections, but it has 
not been confirmed by population-based multicenter studies, in which the incidence of non-GBS diseases 
has remained stable or is even decreasing during a period of increased use of IAP for the prevention of 
GBS EOD. Some single hospital studies have found an increased incidence of neonatal sepsis caused by 
E coli or ampicillin-resistant pathogens but these increases were limited to preterm or low birth weight 
infants. These data are not of sufficient magnitude to outweigh the benefits of IAP to prevent GBS EOD 
but continued surveillance of neonatal sepsis caused by organisms other than GBS is needed. In 
Belgium, a 10-year analysis of the data reported for perinatal sepsis or meningitis by a network of look-
out laboratories shows a significant decrease in non-GBS Gram negative pathogens in recent years. 
 
In 1998-1999, when no official guidelines were available in Belgium, two mail surveys were 
conducted to evaluate the Belgian practices for the prevention of GBS perinatal disease and to appraise 
methods used by microbiology laboratories to detect GBS. All Belgian obstetricians (Flemish-Fl and 
French-Fr Communities) had been invited to participate in one of these surveys, as were clinical 
microbiologists from the French Community.  The guidelines issued by CDC in 1996 were considered as 
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the golden standard for the evaluation.  The results of these surveys showed significant geographical 
differences in the obstetricians’ clinical practice. Among the Fr. obstetricians, 90 % had chosen the 
prenatal screening approach, whereas Fl obstetricians preferred the risk-based approach.  When the risk-
based approach was or had to be considered for the decision to give an IAP, more than 90 % of the Fr 
obstetricians looked for intrapartum fever and prolonged rupture of membranes, and 58 % considered 
also prematurity as a risk factor.  Among Fl obstetricians, respectively 57 %, 36 % and 36 % took the 
three most frequent risk factors into account to decide on an IAP. For their antibioprophylaxis, most 
obstetricians preferred amoxycilline to the recommended penicillin G. Furthermore, the regimen was often 
inadequate.  On the microbiologists’ side, less than 2% used the advised selective enrichment broth for 
the prenatal screening cultures, but at that time this medium was not commercially available in a ready-to-
use form. Microbiologists also reported the usual lack of information on the requesting form, most of the 
time they did not know the prenatal status of the patient. Both surveys also pointed to a lot of room for 
improvements and the need for coordination between medical partners. 
 
3.7. Effectiveness of a risk-based approach versus a screening-based approach 
Though there might be some fear that the screening-based option will lead to more women being 
treated, the numbers will be the same for both strategies if all the risks are closely considered. The US 
experience indicates that compliance to the screening-based option (>90-95 %) is usually better than 
compliance to the risk-based option (45-88 %).  A very important point in the screening-based approach 
is the good documentation of results and the organization to have these at hand at the time of labor. Of 
course, the expense is higher and is caused by the cost of the prenatal screening cultures, but overall 
cost savings due to more cases being prevented is in favor of the screening-based approach. No data are 
available or have been estimated for Belgium, but some projections are available for the US situation 
(table 7).  
Table 7 :   Comparison of some costs and effectiveness of the strategies proposed for the prevention 
of early-onset GBS infection (US simulation, W.E. Benitz 2001) 












Criteria for IAP < 37 w. 
or RF* + 
GBS + 
or < 37 w. 
or RF* + 
 
All parturients 
Patients treated/1,000 births 
Patients treated/case prevented 
% GBS cases prevented 













*RF  = PROM > 18 hours or intrapartum maternal fever >= 38°C 
 
In table 7, “universal” IAP for all women is the most effective approach, but is not acceptable for 
other considerations, and is only mentioned for comparative purposes. It is important to keep in mind that 
no strategy will prevent 100 % of cases. In Belgium no maternal risk factors were found in 60 % of 
infected babies, which means that among these 60 %, not a single infection would have been prevented 
by the risk-based approach.  
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4. CONCLUSIONS 
The recommendations presented develop the point of convergence between an extensive review of 
the literature and the opinions of the working group members.   
This document aims at being a tool for improving the quality of the care given to the “mother-child” 
pair; it is not a constraining document, nor is it a legal reference text. 
 
The recommended strategy for the prevention of perinatal GBS disease is based on a universal 
prenatal screening-approach with the integration of risk-based options when necessary.   
 
Other strategies are still being investigated, such as strategies based on vaginal flushing with 
antiseptics or on the development of real-time PCR for the improvement of GBS screening. If the 
evaluation of those strategies demonstrates their relevance, the recommendations endorsed by this 
document could be affected accordingly.  
 
The point is to implement these recommendations in the daily practice without this resulting in ill-
considered overcosts or an excess of clinical work. Though the advice given to carry out both vaginal and 
anal sampling and to use a selective enrichment medium and an identification medium for GBS screening 
may seem maximalist, one should take into consideration that these conditions considerably improve  
screening efficiency.  
 
Needless to say, the recommendations must be integrated in the standard follow-up of all pregnant 
women as well as in the perinatal management of newborns.   
 
A crucial element of their success lies in the effective transmission of the prenatal GBS screening 
results to the delivery room. A narrow partnership between the obstetrician, the biologist and the 
pediatrician is also essential.  
 
An obvious consequence of their implementation will be the frequent administration of a short-term 
and narrow-spectrum antibiotherapy (penicillin except in case of allergy). To date, no significant increase 
in the incidence of infections with bacteria resistant to prophylaxis has been demonstrated in countries 
where such a strategy has already been implemented.   
 
Complying to these recommendations ensures a decline by 70% of the number of early neonatal 
GBS infections that occur in the absence of any intervention.  
  
Nevertheless, it is not the ideal strategy because it exposes a large number of women to 
unnecessary antibiotherapy. Still, until effective vaccines have been licensed and become available, the 
recommended strategy is rational and effective. 
 
Because of the potential unintended effects of chemoprophylaxis, it is necessary to monitor the 
incidence of serious neonatal infection, the occurrence of pathogens other than GBS and the potential 
emergence of GBS antimicrobial resistance as well as the prevalence of GBS recto-vaginal colonization 
among pregnant women while implementing this prevention strategy. 
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6. APPENDIX 
Specific microbiological media and tests 
LIM Broth 
• Composition : Todd-Hewitt broth + colistin (10 mg/L) +  nalidixic acid (15 mg/L)  
• Intended use : Lim broth is an enriched selective liquid medium used for the isolation of 
GBS, supporting rapid growth of Gram positive organisms while inhibiting the growth of 
numerous Gram negative organisms. 
• Actual distributor in Belgium : Becton Dickinson 
 
ESBM 
 Not commercialized in Belgium at time of writing,  
 Same use  as LIM broth 
 Potential future distributor in Belgium: International Medical 
 
Granada (medium plate) 
 
 Granada agar 
• Intended use : Granada medium allows the direct and easy identification of GBS colonies.  
The development of orange or red colonies is specific (100 %) to  GBS.  
• Producer : Biomedics, Madrid, Spain 
• Presentation : ready to use agar plates or plastic containers with powdered medium to 
prepare 100 ml or 500 ml of Granada medium.   
• Remark : if plates are prepared in-house, it is highly recommended to add 5 % of sterile 
serum and control of the pH is very important. 
• Storage : Store in refrigerator and NOT at room temperature. Storage conditions are critical 
for the quality of the medium.  
• Quality control : Frequently check the performance for production of red-orange colonies, 
with a known GBS strain. 
• Actual distributor in Belgium : International Medical. 
 
Group B Strep Differential agar 
• Intended use : This medium is a variety of Granada medium and may be used instead of  
“Granada medium”. It allows the direct and easy identification of GBS colonies.  The 
development of orange or red colonies is specific (100 %) to  GBS.  
• Producer : Becton Dickinson, BD, Germany. 
• Presentation : ready to use agar plates. 
• Storage : Store in refrigerator and NOT at room temperature. Storage conditions are critical 
for the quality of the medium.  
• Quality control : Frequently check the performance for production of red-orange colonies, 
with a known GBS strain. 
• Actual distributor in Belgium : Becton Dickinson. 
 
Strep B OIA 
 
• Intended use : The Strep B OIA test is a qualitative optical ImmunoAssay (OIA) method for 
the rapid detection of GBS antigen directly from vaginal swabs of intrapartum maternity 
patients.  The test is intended for use as an adjunct to culture, clinical observation and 
information available to the physician.  
• Producer : Thermo-BioStar, Louisville, Colorado, USA 
• Presentation : 30 tests/kit   
• Remark : Each laboratory should verify and validate its own performance with the test. 
• Actual distributor in Belgium : Forlab 
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